BBC:NSD-BioShares Biotechnology Clinical Trials Fund (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 28.023

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

400.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the BioShares Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its total assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The fund is non-diversified.

Inception Date: 16/12/2014

Primary Benchmark: LifeSci Biotech Clinical Trials USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.85%

Management Expense Ratio: 0.79 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV Health Care Select Sector SPDR.. 0.13 %

+0.32 (+0.21%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In.. 0.08 %

+0.19 (+0.26%)

USD 3.02B
FXH First Trust Health Care AlphaD.. 0.63 %

+0.86 (+0.77%)

USD 1.26B
XHE SPDR® S&P Health Care Equipme.. 0.35 %

+1.16 (+1.31%)

USD 0.22B
IDNA iShares Genomics Immunology an.. 0.00 %

+0.65 (+2.67%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF 0.50 %

+1.20 (+3.25%)

USD 0.11B
XHS SPDR® S&P Health Care Service.. 0.35 %

+1.71 (+1.78%)

USD 0.08B
HTEC Robo Global® Healthcare Techn.. 0.00 %

+0.32 (+1.10%)

USD 0.06B
BBP Virtus LifeSci Biotech Product.. 0.79 %

+1.33 (+2.12%)

USD 0.02B
IHF iShares U.S. Healthcare Provid.. 0.43 %

+0.59 (+1.03%)

N/A

ETFs Containing BBC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.60% 81% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.60% 81% B- 73% C
Trailing 12 Months  
Capital Gain 27.77% 100% F 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.77% 100% F 82% B
Trailing 5 Years  
Capital Gain 5.74% 52% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.74% 52% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain -1.15% N/A N/A 31% F
Dividend Return -1.10% N/A N/A 20% F
Total Return 0.06% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 36.33% N/A N/A 27% F
Risk Adjusted Return -3.02% N/A N/A 24% F
Market Capitalization 0.02B 10% F 8% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.